Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Given Consensus Rating of “Hold” by Analysts

Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) have earned an average recommendation of “Hold” from the seven brokerages that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $3.75.

A number of equities analysts have weighed in on HOWL shares. Wall Street Zen lowered Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings downgraded Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 16th.

Insider Buying and Selling

In other Werewolf Therapeutics news, major shareholder Ra Capital Management, L.P. sold 416,911 shares of Werewolf Therapeutics stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $0.35, for a total transaction of $145,918.85. Following the completion of the sale, the insider directly owned 303,719 shares in the company, valued at $106,301.65. The trade was a 57.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Luke Evnin sold 107,429 shares of Werewolf Therapeutics stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $0.31, for a total transaction of $33,302.99. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 4,067,237 shares of company stock worth $2,070,189 over the last ninety days. 23.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Werewolf Therapeutics

Several institutional investors have recently modified their holdings of the company. Bank of America Corp DE raised its stake in shares of Werewolf Therapeutics by 1.2% during the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after acquiring an additional 25,882 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Werewolf Therapeutics by 8.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after purchasing an additional 109,796 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Werewolf Therapeutics by 48.6% during the 4th quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock valued at $429,000 after purchasing an additional 221,766 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Werewolf Therapeutics during the 2nd quarter valued at $409,000. Finally, Citadel Advisors LLC purchased a new position in Werewolf Therapeutics in the 3rd quarter worth $304,000. 64.84% of the stock is currently owned by institutional investors.

Werewolf Therapeutics Trading Down 1.4%

HOWL stock opened at $0.36 on Friday. The firm has a 50 day moving average of $0.40 and a 200-day moving average of $0.61. The firm has a market capitalization of $17.64 million, a P/E ratio of -0.29 and a beta of 0.30. Werewolf Therapeutics has a 12 month low of $0.27 and a 12 month high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.04. Sell-side analysts predict that Werewolf Therapeutics will post -1.08 EPS for the current year.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.